Robeco Institutional Asset Management
SUPN icon

Robeco Institutional Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Robeco Institutional Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,151
Closed -$267K – 918
2025
Q1 		$267K Buy
+8,151
New +$289K ﹤0.01% 873

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Robeco Institutional Asset Management's SUPN Position: Q2 2025 in Review

Robeco Institutional Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2025, closing a stake of 8,151 shares — an estimated $267K sold.

Robeco Institutional Asset Management first reported a position in SUPN in Q1 2025 and held it in 1 quarter. The position peaked at $267K in Q1 2025. 295 funds tracked by Wall St. Rank hold SUPN as of Q2 2025.

  • Robeco Institutional Asset Management reported no remaining Supernus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Robeco Institutional Asset Management sold 8,151 Supernus Pharmaceuticals shares in Q2 2025, an estimated $267K.
  • Robeco Institutional Asset Management first reported a position in Supernus Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Robeco Institutional Asset Management's Supernus Pharmaceuticals position peaked at $267K in Q1 2025.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2025.

Based on Robeco Institutional Asset Management's 13F filing for Q2 2025, filed 18 Jul 2025.